<DOC>
	<DOCNO>NCT00925314</DOCNO>
	<brief_summary>The purpose study assess safety , efficacy , immunological response study product , TLI , adjuvant therapy subject Stage III Melanoma . Normal cell body establish lifespan . Cancer cell hand ability continue divide new cell indefinitely . More 85 % cancer ability enzyme find cancer cell . The Investigational Product , Transgenic Lymphocyte Immunization ( TLI ) , aim help immune system target enzyme find cancerous cell . Subjects meet inclusion exclusion criterion undergo leukapheresis white blood cell collect used manufacture personal study product . Subjects receive 3 infusion TLI roughly 1 month apart follow 2 year period routine laboratory draw , compute tomography ( CT ) scan physical exam .</brief_summary>
	<brief_title>A Study Transgenic Lymphocyte Immunization ( TLI ) Against Telomerase Subjects With Stage III Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject ≥18 year age able understand give write informed consent Women subject childbearing potential ( WOCBP ) male subject must use effective method contraception Histologic diagnosis malignant melanoma : Melanoma primary completely resect negative margin . Primary surgery must &lt; 8 week leukapheresis procedure Stage IIIB Stage IIIC accord American Joint Committee Cancer ( AJCC ) TumorNodeMetastasis ( TNM ) criterion ( Appendix 2 ) OR previously resect Stage I II melanoma recurs Stage IIIB IIIC . HLAA2 positive ECOG Performance Status 0 , 1 2 ( Appendix 3 ) Adequate bone marrow , hepatic , renal function : WBC ≥1500/μL ANC ≥1000/μL Platelets ≥100 × 103/μL Hemoglobin ≥9 g/dL Creatinine ≤2 ULN AST ≤2 ULN Bilirubin ≤2 ULN ( except subject Gilbert 's Syndrome must total bilirubin &lt; 3.0 mg/mL ) Negative screen test HIV , Hepatitis B C Female subject , partner male subject unwilling unable practice abstinence use barrier method ( condom ) intercourse minimize risk exposure bloodborne transgene entire period study 8 week last TLI infusion Known allergy DMSO Any malignancy subject diseasefree less 5 year , exception adequately treat cured basal squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix Primary ocular mucosal melanoma Autoimmune disease : subject document history symptomatic autoimmune disease ( e.g. , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ e.g. , Wegener 's granulomatosis ] ) may require systemic therapy Concomitant therapy anticancer agent ; immunosuppressive agent ; investigational therapy ; chronic use systemic corticosteroid ( used management cancer non cancerrelated illness ) . Replacement dose corticosteroid allow subject adrenal insufficiency Prior biologic therapy melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Stage III Melanoma</keyword>
	<keyword>Melanoma</keyword>
	<keyword>TLI</keyword>
	<keyword>Transgenic Lymphocyte Immunization</keyword>
	<keyword>CB-10-01-02</keyword>
</DOC>